Nuclear factor-κ B inducing kinase is required for graft-versus-host disease

Haematologica

Volumn 95, Issue 12, 2010, Pages 2111-2118

  Sánchez Valdepeñas, Carmen ^a   Casanova, Lucía ^b   Colmenero, Isabel ^b   Arriero, Mar ^b   González, África ^b   Lozano, Nieves ^b   González Vicent, Marta ^b   Díaz, Miguel A ^b   Madero, Luís ^b   Fresno, Manuel ^a   Ramírez, Manuel ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Graft versus host disease; NF b; NF b inducing kinase; NIK

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NUCLEAR FACTOR KAPPA B INDUCING KINASE; PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NF KAPPA B KINASE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL VIABILITY; CHILD; CONTROLLED STUDY; ENZYME DEFICIENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; COLON; CYTOLOGY; ENZYMOLOGY; FLOW CYTOMETRY; GENETICS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; METHODOLOGY; PATHOLOGY; SKIN;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; CHILD; COLON; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; SKIN; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649881910     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.028829     Document Type: Article

References (44)

1. Thomas ED. Bone marrow transplantation: a review. Semin Hematol. 1999;36(4 Suppl 7): 95-103.
2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373(9674): 1550-61.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5): 340-52.
4. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10): 4119-26.
5. Ferrara JLM, Cooke KR, Teshima T. The pathophysiology of graft-vs.-host disease. In Ferrara J, Cooke K and Deeg J eds. Graftvs.- Host Disease, 3rd edition, New York, Marcel Dekker. 2005;1-34.
6. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725-34.
7. Makarov SS. NF-kappaB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today. 2000;6(11):441-8.
8. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest.2001;107(1):7-11
9. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107(2):135-42.
10. Liou HC, Hsia CY. Distinctions between c- Rel and other NF-kappaB proteins in immunity and disease. Bioessays. 2003; 25(8):767-80.
11. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR. NF-kappaB as a target for the prevention of graft-versus- host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006;107 (2):827-34.
12. Jain J, Loh C, Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol. 1995;7(3):333-42.
13. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol. 2006;72(9): 1161-79.
14. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NF-kappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci. 2008;105(9):3503-8.
15. Matsumoto M, Yamada T, Yoshinaga SK, Boone T, Horan T, Fujita S, et al. Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway. J Immunol. 2002;169(3):1151-8.
16. Sánchez-Valdepeñas C, Martín AG, Ramakrishnan P, Wallach D, Fresno M. NFkappaB- inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity. J Immunol. 2006;176(8):4666-74.
17. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4+ T cells do not induce graft-versushost disease. J Clin Invest. 2003;112(1): 101-8.
18. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007;109(7):3115-23.
19. Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, García-Ojeda M, Sibley R, et al. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med. 1999;189(7):1073-81.
20. Elewaut D, Shaikh RB, Hammond KJ, De Winter H, Leishman AJ, Sidobre S, et al. NIK-dependent RelB activation defines a unique signaling pathway for the development of V alpha 14i NKT cells. J Exp Med. 2003;197(12):1623-33.
21. Ishimaru N, Kishimoto H, Hayashi Y, Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat Immunol. 2006;7(7):763-72.
22. Beilhack A, Schulz S, Baker J, Beilhack GF, Wieland CB, Herman EI, et al. In vivo analyses of early events in acute graft-versus- host disease reveal sequential infiltration of T-cell subsets. Blood. 2005,106(3): 1113-22.
23. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chung WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-44.
24. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-30.
25. Saitoh Y, Yamamoto N, Dewan MZ, Sugimoto H, Martinez Bruyn VJ, Iwasaki Y, et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed- Sternberg cells. Blood. 2008;111(10):5118-29.
26. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF- (kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest. 2005;115(7): 1848-54.
27. Jin W, Zhou XF, Yu J, Cheng X, Sun SC. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood. 2009;113(26):6603-10.
28. Lu LF, Gondek DC, Scott ZA, Noelle RJ. NF kappa B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J Immunol. 2005;175(3):1651-7.
29. Fagarasan S, Shinkura R, Kamata T, Nogaki F, Ikuta K, Tashiro K, et al. Alymphoplasia (aly)-type nuclear factor kappaB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. J Exp Med. 2000;191(9):1477-86.
30. Brenner D, Krammer PH, Arnold R. Concepts of activated T cell death. Crit Rev Oncol Hematol. 2008;66(1):52-64.
31. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev. 2003;193:70-81.
32. Schmitz I, Krueger A, Baumann S, Schulze- Bergkamen H, Krammer PH, Kirchhoff S. An IL-2-dependent switch between CD95 signaling pathways sensitizes primary human T cells toward CD95-mediated activation- induced cell death. J Immunol. 2003; 171(6): 2930-6.
33. Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P. Molecular mechanisms of activated T cell death in vivo. Curr Opin Immunol. 2002; 14(3):354-9.
34. Marrack P, Kappler J. Control of T cell viability. Annu Rev Immunol. 2004;22:765-87.
35. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7(7):532-42.
36. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel AE. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol. 2000;165(4):1743-54.
37. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH, et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol. 2004;172(4):2194-200.
38. Wan YY, DeGregori J. The survival of antigen- stimulated T cells requires NFkappaBmediated inhibition of p73 expression. Immunity. 2003;18(3):331-42.
39. Brenner D, Golks A, Kiefer F, Krammer PH, Arnold R. Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death. EMBO J. 2005;24(24):4279-90.
40. Mittal A, Papa S, Franzoso G, Sen R. NFkappaB- dependent regulation of the timing of activation-induced cell death of T lymphocytes. J Immunol. 2006;176(4):2183-9.
41. Ju XP, Xu B, Xiao ZP, Li JY, Chen L, Lu SQ, et al. Cytokine expression during acute graft-versus-host disease after allogeneic peripheral stem cell transplantation. Bone Marrow Transplant. 2005;35(12):1179-86.
42. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006;441(7095): 890-3.
43. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, et al. T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(2):170-8.
44. Yi T, Zhao D, Lin CH, Zhang C, Chen Y, Todorov I, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008;112 (5):2101-10.